Suggested remit - To appraise the clinical and cost effectiveness of intravenous zanamivir within its marketing authorisation for treating influenza in hospital
 
Status Awaiting development
Decision None selected
Process STA pre-2018
ID number 1196

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
30 January 2018 - 27 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual